Physician profile
Pavan Irukulla
NPI 1184860926
$3,373.49
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,833 · 2020: $441 · 2024: $99.59.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $99.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $99.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $550.45 | 2019-2020 | |
| Glaxosmithkline, LLC. | $506.76 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $367.61 | 2019-2020 | |
| Mylan Specialty L.P. | $228.56 | 2019-2020 | |
| Grifols USA, LLC | $197.00 | 2019-2020 | |
| Genentech USA, INC. | $196.77 | 2019-2020 | |
| Insmed, INC. | $151.72 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $140.85 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $140.68 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $132.63 | 2019 | |
| Novartis Pharmaceuticals Corporation | $132.16 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $106.98 | 2019 | |
| Paratek Pharmaceuticals, INC. | $99.59 | 2024 | Nuzyra |
| Circassia INC. | $70.27 | 2019 | |
| Philips North America LLC | $68.79 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $61.49 | 2019 | |
| Genzyme Corporation | $53.43 | 2019 | |
| Mallinckrodt Enterprises LLC | $45.78 | 2019 | |
| United Therapeutics Corporation | $35.22 | 2019 | |
| Veran Medical Technologies, INC. | $27.96 | 2019 | |
| Mallinckrodt Hospital Products INC. | $20.94 | 2020 | |
| Electromed, INC. | $14.65 | 2019 | |
| Merck Sharp & Dohme LLC | $12.37 | 2019 | |
| Pfizer INC. | $10.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pavan Irukulla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.